CD19-targeting UB-VV11 became the first in vivo CAR-T cell therapy to be cleared for human testing by the FDA last year, and ...
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Participants Date & Time : Oct.
The Phase 1b trial will evaluate the safety and tolerability of cemsidomide, an IKZF1/3 degrader, and dexamethasone in combination with elranatamab as a second line or later therapy for patients with ...
The FDA has granted fast track designation to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more prior lines of therapy and relapsed/refractory chronic ...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the ...
COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced today the U.S. Food and Drug Administration ...
Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...
Lu]Lu-PSMA-617 radiopharmaceutical therapy has been approved for the treatment of men with metastatic castration-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback